

Curriculum Vitae

Name: Antonio Medina de Almeida

D.O.B.: 23 / 10 / 1970

Address: Head of Haematology
Hospital da Luz
Avenida Lusitana, 100
1500-650 Lisboa
Portugal

Tel: +351 91 9707747

email: amalmeida@hospitaldaluz.pt

Ordem dos Médicos nº: 35894

Speciality: Haematology

Academic History

Secondary school: St. Julian's School, Carcavelos, Portugal
June 1986: 10 O'Levels
June 1988: International Baccalaureate: Biology, Chemistry,
Physics, Mathematics, Portuguese, French.

University: University of Cambridge
June 1990: BA Hons (Cantab)

Medical School: Addenbrooke's Hospital, Cambridge
Dec. 1993: MB Bchir (Cantab)

Postgraduate qualifications:

Feb 1997: MRCP (Lond)
Sept 2001: MRCPATH
June 2002: Certificate of completion of specialist training (CCST) in Haematology
May 2007: PhD Imperial College

Professional experience

Current Post

Head of Haematology, Hospital da Luz Lisboa

General Hospital with 400 in-patient beds, 24 hour emergency and all medical and surgical specialties. The haematology department consists of 3 specialists and provides

- general and oncological haematology clinics and consultancy for other specialties, including hemoglobinopathies and hemostasis in Lisbon, Oeiras, Amadora and Setúbal.
- Out-patient and in-patient chemotherapy apart from acute leukemias and bone marrow transplantation.
- Bone marrow morphology with special test diagnosis

House jobs

Feb 1994 - Aug 1994

General Surgery, Bedford South Wing Hospital

Aug 1994 - Feb 1995

General Medicine, Addenbrooke's Hospital, Cambridge

SHO rotation: St George's Hospital, Tooting

Feb 1995 - Aug 1995

General Medicine and Chest Medicine

Aug 1995 - Feb 1996

Care of the Elderly

Feb 1996 - Aug 1996

Haematology

Aug 1996 - Feb 1997

Cardiology

St. Bartholomew's Hospital, London

Feb 1997 - Aug 1997

Haematological Oncology

Specialist Registrar Rotation

Aug 1997 - Nov 1998

Hammersmith Hospital, London

Nov 1998 - Feb 2000

Central Middlesex Hospital, London

Feb 2000 - May 2001

Royal Free Hospital, London

May 2001 - Oct 2001

Great Ormond Street Hospital, London

Nov 2001 - Feb 2002

St. Mary's Hospital, London

March 2002 – Sept 2002

Hammersmith Hospital, London

Locum Consultant Posts

Oct 2002 – Feb 2003

St. Thomas's Hospital, London

- Three general haematology clinics per week, one of which slanted towards thrombophilia.
- Supervision of registrar training.
- Responsibility for morphology and liaison with histopathology.
- Management of general laboratory and specials.
- Covering in-patients mainly with sickle cell disease.

- Responsibility for haematological referrals from medical and surgical teams

March 2003 – June 2003 **Newham General Hospital, London**

- District General Hospital
- Responsibility for in-patients and diagnostic laboratory
- Two out-patient clinics per week

Leukaemia Research Fund Clinical Research Fellow

June 2003 – June 2006

Project title: Characterisation of the Biochemical and Genetic Defect in Inherited Paroxysmal Nocturnal Haemoglobinuria

Laboratory-based research project towards a PhD degree attached to Imperial College, University of London (see publications below).

September de 2006: **Instituto Português de Oncologia Franscisco Gentil, Lisboa**

Consultant Haematologist in charge of in-patients and out-patients.

Clinical activity:

Responsible for 13 in-patient beds in a 26 bedded haematology ward

4 weekly clinics with special interest in Myelodysplastic and Myeloproliferative Syndromes.

Education:

Medical students from Universidade Nova de Lisboa as an Assistant Professor

Tutor for 5 hematology trainees, 3 in training and 2 successfully completed in 2011 and 2016

Chairman of EHA Curriculum Committee

Member of EHA Educational Committee

Board and Executive Board Member EHA

Research:

“Epigenetic modifications in Fanconi Anemia: role in disease progression and effects of DNA hypomethylation and histone deacetylase inhibition”

Investigador Principal: António Almeida

Funding: Associação Portuguesa Contra a Leucemia 2011

NRS Liga Portuguesa Contra o Cancro – Terry Fox, 2013

“Epigenetic modification in myeloproliferative neoplasms: molecular mechanisms and effects of histone deacetylase inhibition and DNA hypomethylation”

Investigador Principal: António Almeida

Funding: Fundação para a Ciência e Tecnologia 2012 post-doctoral fellowship

“Transcriptional regulation of the mannosyltransferase-encoding gene PIGM by GATA family transcription factors in Inherited Glycosylphosphatidylinositol Deficiency (IGD)”

Investigador Principal: António Almeida

Funding: Fundação para a Ciência e Tecnologia 2009 doctoral fellowship

“Transcriptional control of housekeeping genes by histone acetylation and SP1: molecular mechanisms and therapeutical potencial”.

Investigador Principal: António Almeida

Funding: Associação Portuguesa Contra a Leucemia 2009”

Fundação para a Ciência e Tecnologia 2008 post-doctoral fellowship

Clinical trials and registries as principal investigator:

GCP training completed March 2016

- MDS-005: randomized double blind phase 3 trial of Lenalidomide versus placebo in lower risk transfusion-dependent MDS without 5q deletion
- EPIC: randomized open label phase 3 trial of Ponatinib versus Imatinib in newly diagnosed patients with chronic phase CML
- AZA-AML-001: randomized double blind phase 3 trial of oral Azacitidine versus placebo in AML patients in complete remission
- AZA-MDS-003: randomized double blind phase 3 trial of oral Azacitidine versus placebo in lower risk thrombocytopenic and transfusion-dependent MDS patients without deletion 5q
 - Member of trial steering committee
- EUROSki : multicenter trial to assess the persistence of molecular responses in patients with CML following TKI interruption
- ENESTPath : multicentre single arm trial to assess the efficacy of Nilotinib in achieving MR⁴ and treatment interruption in CML patients in MR³ with Imatinib
- REAP : Extended access of Ruxolitinib in Polycythemia Vera patients who are resistant or intolerant to Hydroxyurea
- OPTIC 2L : A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
- OPTIC : A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
- FUSION-MDS-AML : A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF AZACITIDINE SUBCUTANEOUS IN COMBINATION WITH DURVALUMAB (MEDI4736) IN PREVIOUSLY UNTREATED SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR IN ELDERLY (≥ 65 YEARS) ACUTE MYELOID LEUKEMIA (AML) SUBJECTS NOT ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FUSION HR MDS/ELDERLY AML 001 STUDY

National co-ordinator of:

- International PNH registry
- EUTOS European CML registry
- EUMDS European MDS registry

Member of collaborative groups and societies:

Grupo Português de Mielodisplasias (Portuguese MDS group)

Grupo Português de Leucemia Mielóide Crónica (Portuguese CML group - lead)

European LeukemiaNet

European Haematology Association

American Society for Haematology
COSMYD: European myeloproliferative group

Member of editorial board

- Leukemia Research
- Leukemia Research Reports

Regular reviewer

- Leukemia Research
- PloSOne
- Oncotarget
- Hematologica

Publications

Almeida, AM, Henthorn, J, Davies, SC, Neonatal Screening for Haemoglobinopathies: the results of a ten year programme in an English health region, **British Journal of Haematology** (2001), **112**, pp. 32-35.

McCloy, M, **Almeida, A**, Daly, P, Vulliamy, T, Roberts, I, Dokal, I, Short Report: Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation, **British Journal of Haematology** (2001), **112**, pp. 427-429.

Almeida, A, Khair, K, Hann, I, Liesner, R. Unusual presentation of Factor XIII deficiency. **Haemophilia** (2002), **8**, pp. 703-705.

Almeida, AM, Khair, K, Hann, I, Liesner, R. The use of recombinant factor VIIa in children with inherited platelet function disorders, **British Journal of Haematology** (2003), **121**, pp. 477-81

Amrolia, P, **Almeida, AM**, Halsey, C, Davies, SC, Roberts, I. Therapeutic challenges in sickle cell disease Part 1: current and future treatment options. **British Journal of Haematology** (2003) **120**, pp. 725-36

Amrolia, P, **Almeida, AM**, Davies, SC, Roberts, I. Therapeutic challenges in sickle cell disease Part 2: a problem-orientated approach. **British Journal of Haematology** (2003) **120**, pp. 737-43

Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, **Almeida A**. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. **Blood Coagulation and Fibrinolysis**. (2003), **14**, pp. 735-9.

Henthorn JS, **Almeida AM**, Davies SC. Neonatal Screening for Sickle Cell Disorders. **British Journal of Haematology**. (2004), **124**, pp. 259-63.

Daniel Y, Witchlow B, **Almeida A**. Automated computer result reporting for haemoglobinopathy screening. **Clinical and Laboratory Haematology**, (2004), **26**, pp. 21-4.

Almeida A, Roberts I. Bone involvement in Sickle Cell Disease. **British Journal of Haematology**, (2005), **129**, pp.482-90.

Patterson S, Kotsianidis I, **Almeida A**, Politou M, Rahemtulla A, Matthew B, Schmidt RR, Cerundolo V, Roberts IA, Karadimitris A. Human invariant NKT cells are required for effective in vitro alloresponses. **Journal of Immunology**, (2005), **175**, pp5087-94

Kotsianidis I, Silk JD, Spanoudakis E, Patterson S, **Almeida A**, Schmidt RR, Tsatalas C, Bourikas G, Cerundolo V, Roberts IA, Karadimitris A. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. **Blood**. (2006) **107(8)**, pp 3138-44.

Almeida AM, Murakami Y, Layton DM, Hillmen P, Sellick GS, Maeda Y, Richards S, Patterson S, Kotsianidis I, Mollica L, Crawford DH, Baker A, Ferguson M, Roberts I, Houlston R, Kinoshita T, Karadimitris A. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. **Nature Medicine**. (2006), **12(7)**, pp 846-51.

A.Almeida AM, Murakami Y, Baker A, Maeda Y, Roberts IA, Kinoshita T, Layton DM, Karadimitris A. Targeted therapy for inherited GPI deficiency. **New England Journal of Medicine**. 2007; 356(16):1641-7.

Almeida AM, Layton, DM. *Sickle Cell Disease* in **Conn's Current Therapy 2008**. Elsevier, USA.

Almeida A, Layton M, Karadimitris A. Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. *Biochim Biophys Acta*. 2009 Sep;1792(9):874-80. Epub 2009 Jan 9.

Almeida A, Layton M, Karadimitris A. Inherited GPI Deficiency. Chapter 16, **The Enzymes**, Vol. XXVI, 2009.

Almeida A, Castro I, Coutinho J, Guerra L, Marques H, Pereira AM. Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia *Acta Med Port*. 2009 Sep-Oct;22(5):537-44. Epub 2009 Oct 22.

Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, Xicoy B, **Almeida A**, Guerci-Bresler A, Sliwa T, Muus P, Porter J, Hofmann WK. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. *Leuk Res*. 2011 Sep;35(9):1131-5.

Michael Thorpe; Ana Montalvão; Filipa Moita; Francesca Pierdomenico; **Antonio Almeida**. Treatment of chronic myelomonocytic leukaemia with 5-azacitidine: a case series and literature review. *Leukemia Research*, Epub May 2012

Francesca Pierdomenico; **Antonio Almeida**. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. *Leukemia Research*. 2012 Aug;36(8):1071-3. Epub May 21

Silva, G., Cardoso, B. Belo, H., **Almeida, A.** Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One, January 2013 | Volume 8 | Issue 1 | e53766

Pierdomenico F, Esteves S, **Almeida A.** Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann Hematol. 2013 Apr 21.

Pierdomenico F, **Almeida A.** Treatment of Acute Erythroleukemia with Azacytidine: a case series. Leukemia Research Reports. May 2013

Almeida A., Modifying disease in CMML: who responds to Azacitidine? Leukemia Research 2013 Jun;37(6):603-4.

António Almeida, Hematologia na mulher pós-menopausa. Capítulo no livro MEDICINA NA MULHER PÓS-MENOPAUSA, Editora Lidel 2014

Almeida A., Optimizing treatments in rare diseases: will our evidence come from registry data? Leukemia Research 2014 38: 421-422

Lindberg EH, **Almeida A,** Enoksson F, de Wit TD, Strivens J, Naeve A, Toh CH. Survey of professional competence in hematology in Europe. Haematologica. 2014 Mar;99(3):404-8.

Joana R. Costa, Valentina Sofia Caputo, Kalliopi Makarona, D Mark Layton, Irene AG Roberts, **Antonio Almeida,** and Anastasios Karadimitris. Cell type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPI deficiency. Blood 2014. In press

Louise de Swart, Alex Smith, Thomas Johnston, Detlef Haase, Jackie Droste, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Eva Hellström-Lindberg, Jaroslav Cermak, Ulrich Germing, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, **Antonio Medina Almeida,** Krzysztof Mądry, Borhane Slama, Agnes Guerci-Bresler, Laurence Sanhes, Odile Beyne-Rauzy, Elisa Luno, David Bowen and Theo de Witte. Validation of the Revised International Prognostic Scoring System (IPSS-R) in patients with Lower-risk Myelodysplastic Syndromes: a Report from the Prospective European LeukemiaNet MDS (EUMDS) Registry, **BJH** 2015

Hélio Belo, Gabriela Silva, Bruno A Cardoso, Beatriz Porto, Jordi Minguillon, José Barbot, Jorge Coutinho, Jose A. Casado, Manuela Benedito, Hema Saturnino, Emília Costa, Juan A. Bueren, Jordi Surrallés, **Antonio Almeida.** Epigenetic alterations in Fanconi anaemia: Role in pathophysiology and therapeutic potential. PLoS ONE 2015 Oct

Cardoso BA, Belo H, Barata JT, **Almeida AM**. The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways. *PLoS One*. 2015 Dec 1;10(12)

Roboz GJ, Fernandez PM, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayer S, Porkka K, Marlton P, **Almeida A**, Mohan S, Ravandi-Kashani F, Skikne B, Kantarjian H. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. *Future Oncol*. 2016 Jan 19. [Epub ahead of print]

Guillermo Garcia-Manero, **Antonio Almeida**, Aristoteles Giagounidis, Uwe Platzbecker, Regina Garcia, Maria Teresa Voso, Stephen R. Larsen, David Valcarcel, Lewis R. Silverman, Barry Skikne and Valeria Santini. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. *BMC Hematology* 16:12 DOI: 10.1186/s12878-016-0049-5

Valeria Santini, **Antonio Almeida**, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert Hoenekopp, C.L. Beach and Pierre Fenau. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. *JCO* June 27, 2016 JCO6601

Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. *Leuk Res Rep*. 2016 Jun 16;6:1-7. doi: 10.1016/j.lrr.2016.06.001

Joana Maria Saraiva Diamond, **António Medina de Almeida**, Hélio José Loureço Miguéns Rodrigues Belo, Manuela Paula Guerra Pinheiro Gameiro da Costa, José Manuel Valente Sequeira Cabeçadas, Manuel Maria de Sousa Ferreira Abecasis. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene. *Ann Hematol* DOI 10.1007/s00277-016-2827-3, Oct 2016.

Almeida A, Fenau P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). *Leuk Res*. 2016 Nov 13;52:50-57. doi: 10.1016/j.leukres.2016.11.008

Urbano-Ispizua A, Muus P, Schrezenmeier H, **Almeida A**, Wilson A, Ware RE. Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. *Haematologica*. 2016 Nov 24. pii: haematol.2016.151852

António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, and Ricardo Pinto. Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study. *Leuk Res Rep*. 2017; 7: 6–10.

Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, **Almeida AM**, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porrás JRG, Del Cañizo C, Sánchez-Guijo F. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target? *Oncotarget*. 2017 Apr 25;8(17):28187-28202..

Antonio M. Almeida, Thomas Prebet, Raphael Itzykson, Fernando Ramos, Haifa Al-Ali, Jamile Shammo, Ricardo Pinto, Luca Maurillo, Jaime Wetzel, Pellegrino Musto, Arjan A. Van De Loosdrecht, Maria Joao Costa, Susana Esteves, Sonja Burgstaller, Reinhard Stauder, Eva M. Autzinger, Alois Lang, Peter Krippel, Dietmar Geissler, Jose Francisco Falantes, Carmen Pedro, Joan Bargay, Guillermo Deben, Ana Garrido, Santiago Bonanad, Maria Diez-Campelo, Sylvain Thepot, Lionel Ades, Wolfgang R. Sperr, Peter Valent, Pierre Fenaux, Mikkael A. Sekeres, Richard Greil and Lisa Pleyer. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. *Int. J. Mol. Sci*. 2017, 18, 837; doi:10.3390

Almeida AM, Bedrosian C, Cole A, Muus P, Schrezenmeier H, Szer J, Rosse WF. Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Haemoglobinuria Registry. *Intern Med J*. 2017 Jun 13.

José Falantes, Lisa Pleyer, Sylvain Thépot, **António M. Almeida**, Luca Maurillo, Violeta Martínez-Robles, Reinhard Stauder, Raphael Itzykson, Ricardo Pinto, Adriano Venditti, Joan Bargay, Sonja Burgstaller, María Pilar Martínez, Valerie Seegers, Emilia Cortesão, María Ángeles Foncillas, Claude Gardin, Pau Montesinos, Pellegrino Musto, Pierre Fenaux, Richard Greil, Miguel Angel Sanz, Fernando Ramos & for the European ALMA + Investigators. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score:

results from the expanded international E-ALMA series (E-ALMA+). *Leuk Lymphoma*. 2017 Aug 24;1-8. doi: 10.1080/10428194.2017.1365854.

Antonio Almeida, Pierre Fenaux, Guillermo Garcia-Manero, Stuart L. Goldberg, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Carmen Castaneda, Jianhua Zhong, C. L. Beach & Valeria Santini. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. *Leuk Lymphoma*. 2018

Louise de Swart, Alex Smith, Detlef Haase, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermak, Guillermo Sanz, Reinhard Stauder, Moshe Mittelman, Eva Hellström-Lindberg, Luca Malcovati, Saskia Langemeijer, Mette Skov-Holm, Krzysztof Mądry, Ulrich Germing, **Antonio Medina Almeida**, Aurelia Tatic, Aleksandar Savic, Njetočka Gredelj Šimec, Corine van Marrewijk, Agnes Guerzi-Bresler, Laurence Sanhes, Elisa Luño, Dominic Culligan, Odile Beyne-Rauzy, Sonja Burgstaller, Nicole Blijlevens, David Bowen, Theo de Witte. Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. *Leukemia Research*. Volume 67, April 2018, Pages 21–26

Valeria Santini, **Antonio Almeida**, Aristoteles Giagounidis, Uwe Platzbecker, Rena Buckstein, C.L. Beach, Shien Guo, Arman Altincatal, Chengqing Wu, Pierre Fenaux. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. *Clinical Lymphoma, Myeloma and Leukemia*. February 2018. Volume 18, Issue 2, Pages 136–144.e7

Saglio G, Sharf G, **Almeida A**, Bogdanovic A, Bombaci F, Čugurović J, Deekes N, Garcia-Gutiérrez V, de Jong J, Narbutas Š, Westerweel P, Zackova D. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. *Clin Lymphoma Myeloma Leuk*. 2018 Apr 25. pii: S2152-2650(18)30385-9. doi: 10.1016/j.clml.2018.04.005.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, **Almeida A**, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. *Lancet Oncol*. 2018 May 4. pii: S1470-2045(18)30192-X. doi: 10.1016/S1470-2045(18)30192-X.

Almeida A. Hematology training in Europe. International Society for Laboratory Hematology 2018 Education Issue Volume40, IssueS1. May 2018. Pages 137-138. doi: 10.1111/ijlh.12815

Almeida, A.M.; Ar, C.; Hellström-Lindberg, E.; Hollegien, W.W.G.; Navarro, J.T.; Saris, M.T.; Wondergem, M.J.; Toh, C.H. The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility. HemaSphere: June 2018 - Volume 2 - Issue 3 - p e49

Almeida A. Should more MDS patients be treated with immune-suppression? Leuk Res. 2018 Aug;71:25-26. doi: 10.1016/j.leukres.2018.06.011. Epub 2018 Jun 19

Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, **Almeida A**, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018 Aug 28;2(16):2063-2071.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, **Almeida AM**, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Adv. 2018 Aug 28;2(16):2079-2089.

Ana G. Almeida, **António Almeida**, Teresa Melo, Lurdes Guerra, Luís Lopes, Patrícia Ribeiro, Marta Duarte, Alexandra Mota, Ricardo Fontes-Carvalho. Novas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacina em doentes com leucemia mieloide crónica. New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Rev Port Cardiol. 2019 Jan;38(1):1-9.

Cerveira N, **Almeida A.** Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy. J Clin Oncol. 2019 Jan 1;37(1):89-90

Cardoso BA, Ramos TL, Belo H, Vilas-Boas F, Real C, **Almeida AM.** Vorinostat synergizes with Antioxidant therapy to target Myeloproliferative Neoplasms. Exp Hematol. 2019 Feb 12. pii: S0301-472X(19)30069-4. doi: 10.1016/j.exphem.2019.02.002.

Alves R, Gonçalves AC, Jorge J, Alves J, Alves da Silva A, Freitas-Tavares P, Nascimento Costa JM, **Almeida AM**, Sarmiento-Ribeiro AB. Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia. Med Oncol. 2019 Feb 22;36(3):30. doi: 10.1007/s12032-019-1253-5.

Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V. Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. *Clin Lymphoma Myeloma Leuk*. 2019 Apr;19(4):213-219

Marlijn Hoeks, Ge Yu, Saskia Langemeijer, Simon Crouch, Louise de Swart, Pierre Fenaux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström-Lindberg, Guillermo Sanz, Reinhard Stauder, Mette Skov Holm, Moshe Mittelman, Krzysztof Mądry, Luca Malcovati, Aurelia Tatic, **Antonio Medina Almeida**, Ulrich Germing, Aleksandar Savic, Njetočka Gredelj Šimec, Dominic Culligan, Raphael Itzykson, Agnes Guerci-Bresler, Borhane Slama, Arjan van de Loosdrecht, Corine van Marrewijk, Jackie Droste, Nicole Blijlevens, Marian van Kraaij, David Bowen, Theo de Witte, Alex Smith, EUMDS Registry Participants. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. *Haematologica* Jul 2019, haematol.2018.212332; DOI: 10.3324/haematol.2018.212332

Foltz L, Pica GM, Zerazhi H, Van Droogenbroeck J, Visanica S, Báez de la Fuente E, Leber B, **de Almeida AM**, Ranta D, Kiladjan JJ, Chrit L, Kandra A, Morando J, Devos T. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. *Leuk Lymphoma*. 2019 Jul 30:1-10. doi: 10.1080/10428194.2019.1636985.

Almeida A, Pierdomenico F, Guerrero BP, Saraiva F, Montalvão A, Coutinho J, Mariz M, Melo T, Santos MJ, Pereira A, Cerveira N. Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice. *Acta Med Port*. 2019 Aug 1;32(7-8):550-557

Cerveira N, Diamond J, Matos S, Amorim ML, Coucelo M, Bizarro S, Simões AT, Pierdomenico F, Lopes M, Ribeiro L, do Carmo-Fonseca M, Guimarães JE, **Almeida A**, Teixeira MR. Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission. *Br J Haematol*. 2019 Sep;186(6):e181-e184

Gyan E, **Almeida AM**. Less iron improves MDS haematopoiesis. *Br J Haematol*. 2019 Oct;187(1):11-12.

Lopes-Coelho F, Silva F, Gouveia-Fernandes S, Martins C, Lopes N, Domingues G, Brito C, **Almeida AM**, Pereira SA, Serpa J. Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis. *Cells*. 2020 Jan 1;9(1). pii: E107. doi: 10.3390/cells9010107.

Valeria Santini, **Antonio Almeida**, Aristoteles Giagounidis, Barry Skikne, CL Beach, Jerry Weaver, Nora Tu & Pierre Fenaux. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. *Leukemia & lymphoma*. Jan 2020. doi.org/10.1080/10428194.2020.1719088

Kristina Stojkov, Tobias Silzle, Georg Stussi, David Schwappach, Juerg Bernhard, David Bowen, Jaroslav Čermák, Avinash Dinmohamed, Corien Eeltink, Sabrina Eggmann, Pierre Fenaux, Ulrich Germing, Manuel Haschke, Eva Hellstrom-Lindberg, Monika Heger, Arjan Van de Loosdrecht, Jakob Passweg, Michael Pfeilstöcker, Uwe Platzbecker, Luca Malcovati, **Antonio Almeida**, Moshe Mittelman, Christine Morgenthaler, David Steensma, Valeria Santini, Reinhard Stauder, ARGIRIS SYMEONIDIS, Sämi Schär, Charlotte Maddox, Theo de Witte, Julia Bohlius, and Nicolas Bonadies. Guideline-Based Indicators for Adult Patients with Myelodysplastic Syndromes. *Blood Adv*. Jul 2020.

Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Uwe Platzbecker, Alan List, Torsten Haferlach, Jianhua Zhong, Chengqing Wu, Konstantinos Mavrommatis, C.L. Beach, Kyle MacBeth, and **Antonio Almeida**. Impact of somatic mutations on response to lenalidomide in lower-risk non del(5q) myelodysplastic syndromes patients. *Leukemia*, Jul 2020

Andrew H Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun-Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kizil Çakar, Aida Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C L Beach, Gail J Roboz, **QUAZAR AML-001 Trial Investigators** Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. *N Engl J Med*. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.

Lisa Pleyer, Michael Leisch, Alexandra Kourakli, Eric Padron, Jaroslaw Pawel Maciejewski, Blanca Xicoy Cirici, Jennifer Kaivers, Johanna Ungerstedt, Sonja Heibl, Peristera Patiou, Anthony Michael Hunter, Elvira Mora, Klaus Geissler, Maria Dimou, Maria-José Jimenez Lorenzo, Thomas Melchardt, Alexander Egle, Athina-Nora Viniou, Bhumika Jayantibhai Patel, Montserrat Arnan, Peter Valent, Christoforos Roubakis, Teresa Bernal Del Castillo, Athanasios Galanopoulos, Marisa Calabuig Muñoz, Nicolas Bonadies, **Antonio Medina de Almeida**, Jaroslav Cermak, Andrés Jerez, Maria Julia Montoro, Albert Cortés, Alejandro Avendaño Pita, Bernardo Lopez Andrade, Eva Hellstroem-Lindberg, Ulrich Germing, Mikkael Aaron Sekeres, Alan Francis List, Argiris Symeonidis, Guillermo Francisco Sanz, Julian Larcher-Senn, Richard Greil. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-

curative therapies: a retrospective cohort study. *Lancet Haematol.* 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4.

António Almeida. American Society of Hematology 2020 Podcast Collection: MDS and AML. *Advances in Therapy* volume 38, pages 31–35 (2021)

Esther Natalie Oliva, Sarah M Ronnebaum, Omer Zaidi, Dipen A Patel, Salem Abi Nehme, Clara Chen, Antonio M Almeida. A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia. *Am J Blood Res* 2021;11(4):325-360.

Languages:

Competent in spoken and written language: Portuguese, English, French, Italian, Spanish

A handwritten signature in dark ink, appearing to read 'A. Almeida', with a long horizontal stroke extending to the right.

Lisbon, 15/09/2021